Our look is new. Our purpose is the same. Learn more about our brand evolution.
Building tools to accelerate drug development and clinical trials In the pioneering days of the Society, all our research funding went to basic research aimed at discovering the genetic cause […]
How projects we have funded will help us get more and better treatments to our community by June Kinoshita, FSHD Society Many of you have heard us describe the FSHD […]
Steady improvement seen in data from open-label extension study Losmapimod, a drug that is currently in a Phase 3 clinical trial for FSH muscular dystrophy, continues to slow or stop […]
Updated 12-12-24 to reflect the chance in name from Epic Bio to Epicrispr Biotechnologies. Leading-edge CRISPR biotech chooses FSHD as its first disease target Epicrispr Biotechnologies, based in the San […]
She leaves a legacy of remarkable progress toward treatments for FSHD The FSHD Society was deeply saddened to learn of the passing of Corinne Bronfman on October7, in Washington DC. […]
